Orphazyme delays annual report again after striking deal with Kempharm
Orphazyme has provided yet another new date for the release of its 2021 annual report, following the biotech firm’s deal to sell its business to Kempharm. Almost three months have passed since the original release date.
.jpg)
by christopher due karlsson, translated by daniel pedersen
Orphazyme, a listed company in Denmark that has been restructuring since March, has postponed its annual report for 2021 yet again, a company press release states.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme sells entire business to US biotech company
For subscribers
Orphazyme didn't know buyer before negotiations began
For subscribers
Orphazyme reveals new release date for 2021 report
For subscribers
